SenesTech Inc (NASDAQ:SNES) Reports Mixed Q3 2025 Results with Record Revenue but Stock Decline

Last update: Nov 11, 2025

SenesTech Inc (NASDAQ:SNES) has released its financial results for the third quarter of 2025, presenting a mixed picture for investors. The company reported record revenue and highlighted significant growth in its core product line, yet its stock experienced a notable decline in after-hours trading following the announcement.

Third Quarter Financial Results Versus Estimates

The company's performance against analyst expectations reveals a split outcome. While SenesTech fell short on the top line, it demonstrated improved operational efficiency on the bottom line.

Revenue: Reported $690,000 against estimates of $744,600, representing a miss of approximately 7.3%.
Earnings Per Share (Non-GAAP): Reported -$0.28 per share, notably better than the estimated -$0.357.

This divergence suggests that while sales did not meet projections, the company managed its costs effectively, leading to a smaller-than-expected loss per share.

Market Reaction and Recent Performance

The immediate market reaction to the earnings release was negative. The stock was down over 8% in after-market trading, indicating investor focus may have been on the revenue miss. This short-term reaction contrasts with the stock's performance over recent weeks.

After-Market Performance: -8.05%
Last Week: +0.06%
Last Two Weeks: -0.06%
Last Month: -0.15%

The sharp after-hours drop appears to be a direct response to the earnings data, overshadowing the stock's relative stability in the preceding weeks.

Press Release Highlights and Strategic Position

Beyond the specific earnings figures, the company's press release emphasized several positive operational milestones. The headline focused on a 77% growth in revenue from its Evolve® Rodent Birth Control™ products, underscoring the commercial traction of its flagship offering. SenesTech also highlighted a strong cash balance and stated it is making progress toward achieving profitability, which aligns with the better-than-expected EPS figure. As the sole manufacturer of EPA-compliant rodent birth control, the company continues to leverage its unique position in the pest management market.

Forward-Looking Expectations

Looking ahead, analyst estimates provide a benchmark for the company's upcoming performance. For the next quarter (Q4 2025), the consensus is for sales of $893,520 and an EPS of -$0.3366. For the full year 2025, analysts are projecting sales of $2.77 million. The press release did not provide a specific financial outlook from management, so these analyst estimates stand as the current market expectation against which future results will be measured.

For a detailed breakdown of historical earnings and future analyst estimates, you can review the data here.

Disclaimer: This article is for informational purposes only and is not intended as investment advice. The author has no position in SENESTECH INC (SNES). All investments involve risk, and readers should conduct their own research before making any investment decisions.